Vaxart Files Definitive Additional Materials Proxy Statement
Ticker: VXRT · Form: DEFA14A · Filed: May 29, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | DEFA14A |
| Filed Date | May 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, corporate-governance, filing-update
TL;DR
Vaxart filed proxy docs, likely for shareholder votes. Keep an eye on what they're asking for.
AI Summary
Vaxart, Inc. filed a Definitive Additional Materials proxy statement on May 29, 2025. This filing relates to the company's proxy solicitation efforts. Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Why It Matters
This filing indicates Vaxart is actively engaging with shareholders regarding company matters, which could impact future corporate decisions and shareholder value.
Risk Assessment
Risk Level: low — This is a routine filing related to proxy statements, not indicating immediate financial or operational risk.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials proxy statement filed by Vaxart, Inc. on May 29, 2025, indicating it is part of the company's proxy solicitation efforts.
When was Vaxart, Inc. previously known by other names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (name change 20160413), Biota Pharmaceuticals, Inc. (name change 20121113), and NABI BIOPHARMACEUTICALS (name change 20100719).
What is Vaxart, Inc.'s primary business classification?
Vaxart, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) with SIC code 2836.
Where is Vaxart, Inc. located?
Vaxart, Inc.'s business and mailing address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080.
What is Vaxart, Inc.'s fiscal year end?
Vaxart, Inc.'s fiscal year ends on December 31.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 29, 2025 regarding Vaxart, Inc. (VXRT).